drugset
drugset / Trial / NCT01677455

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

NCT01677455 ↗

Phase 2 Completed 51 enrolled Synta Pharmaceuticals Corp.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.

Timeline

Start
2012-07
Primary completion
2015-04
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule 150 mg/m2 Intravenous

Indications

HER2 positive breast carcinoma triple-negative breast carcinoma